Last reviewed · How we verify
Physician's Choice of Endocrine Therapy
Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells.
Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells. Used for Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
At a glance
| Generic name | Physician's Choice of Endocrine Therapy |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Selective estrogen receptor degrader (SERD) |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This drug works by selectively targeting and blocking estrogen receptors in breast cancer cells, which can slow or stop the growth of these cells. By doing so, it can help to reduce the risk of cancer recurrence or slow the progression of the disease.
Approved indications
- Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Musculoskeletal pain
Key clinical trials
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) (PHASE2)
- Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (PHASE3)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PHASE2)
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） (PHASE3)
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician's Choice of Endocrine Therapy CI brief — competitive landscape report
- Physician's Choice of Endocrine Therapy updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI